Cepheid (CPHD) is Downgraded by Robert W. Baird to Neutral, Lowers Price Target to $ 53

Cepheid (CPHD) was Downgraded by Robert W. Baird to ” Neutral” while Lowering the Price Target of the company shares to $ 53 from a previous price target of $53 . Earlier the firm had a rating of “Outperform ” on the company shares. Robert W. Baird advised their investors in a research report released on Sep 12, 2016.

Many Wall Street Analysts have commented on Cepheid. Cepheid was Downgraded by Citigroup to ” Neutral” on Sep 8, 2016. Cepheid was Downgraded by Piper Jaffray to ” Neutral” on Sep 6, 2016.

On the company’s financial health, Cepheid reported $0.05 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.00. The company had revenue of $146.00 million for the quarter, compared to analysts expectations of $145.92 million. The company’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.06 EPS.

Cepheid opened for trading at $52.43 and hit $52.71 on the upside on Wednesday, eventually ending the session at $52.65, with a gain of 0.23% or 0.12 points. The heightened volatility saw the trading volume jump to 6,641,056 shares. Company has a market cap of $3,844 M.

In a different news, on Aug 17, 2016, Scott A. Campbell (Corporate VP & CRO) sold 287 shares at $36.16 per share price. According to the SEC, on May 3, 2016, Peter V. Farrell (EVP, Worldwide Commercial Ops) sold 390 shares at $28.90 per share price. On Apr 27, 2016, John L Bishop (Chairman of the Board and CEO) sold 110,000 shares at $35.50 per share price, according to the Form-4 filing with the securities and exchange commission.

Cepheid is a molecular diagnostics company. The Company develops manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps including sample preparation DNA amplification and detection. The Company’s systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system which integrates sample preparation in addition to DNA amplification and detection serves reference laboratories and hospital central laboratories to satellite testing locations such as emergency departments and intensive care units within hospitals as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system which integrates DNA amplification and detection to allow rapid analysis of a sample.


Leave a Reply

Cepheid - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cepheid. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.